Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study-Reference-Cited by-同舟云学术

Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study

Published:2022-12 Issue:18 Volume:11 Page:1323-1336
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:J. Comp. Eff. Res.

Author:

Brendle Madeline¹²^ORCID,Ahuja Sachin²,Valle Maisa Della²,Moore Claire²,Thielking Paul²,Malone Daniel C¹,Robison Reid²³

Affiliation:

1. Department of Pharmacotherapy, University of Utah College of Pharmacy, UT 84112, USA

2. Numinus Wellness, UT 84020, USA

3. University of Utah School of Medicine, UT 84132, USA

Abstract

Aim: There is limited real-world evidence for patients with treatment-resistant depression (TRD) receiving esketamine nasal spray. Methods: This retrospective cohort study used data collected from a psychiatric clinic's EHR system. Results: A total of 171 TRD patients received esketamine July 2019–June 2021. This predominantly female, white population had several mental health comorbidities and high exposure to psychiatric medications. We observed significant reductions (p < 0.001) in average PHQ-9 and GAD-7 scores from baseline (PHQ-9: mean: 16.7; SD: 5.8; GAD-7: mean: 12.0; SD: 5.8) to last available treatment (PHQ-9: mean: 12.0; SD: 6.4; GAD-7: mean: 8.7; SD: 5.6). There were no reports of serious adverse events. Conclusion: This study found a significant disease burden for patients with TRD. Esketamine appears to be well tolerated and effective in improving depression and anxiety.

Publisher

Becaris Publishing Limited

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer-2022-0149

Reference38 articles.

1. Hough D. Esketamine. Janssen Pharmaceutical Companies of Johnson and Johnson (2019).

2. Major depression. https://www.nimh.nih.gov/health/statistics/major-depression#part_155028

3. Pharmacological approaches to the challenge of treatment-resistant depression;Ionescu DF;Dialogues Clin. Neurosci.,2015

4. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report;Rush AJ;Am. J. Psychiatry,2006

5. Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database;Amos TB;J. Clin. Psychiatry,2018

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression;Biomarkers in Neuropsychiatry;2024-12

2. Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray;International Journal of Psychiatry in Clinical Practice;2024-09-02

3. A Multi-Center, Open-Label, Single-Arm Study to Investigate the Early Effectiveness of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Using a Mobile Self-Monitoring Application;Pharmaceuticals;2024-08-30

4. Glutamatergic Modulators for Major Depression from Theory to Clinical Use;CNS Drugs;2024-08-16

5. Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment;Journal of Psychopharmacology;2024-08-07